Approvals of Janssen's daratumumab and Bristol-Myers Squibb's elotuzumab cap a stellar year for multiple myeloma therapies, providing two new mechanisms of action and prompting a slew of combination trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kingwell, K. Age of antibody therapeutics dawns for multiple myeloma. Nat Rev Drug Discov 15, 5–6 (2016). https://doi.org/10.1038/nrd.2015.39
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2015.39